The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://declanauvp333801.vigilwiki.com/7402158/retatrutide_vs_tirzepatide_a_comparative_analysis